Minecoside

Minecoside is a CXCR4/STAT3 inhibitor with anticancer and anti-inflammatory activity. Minecoside decreases CXCR4 expression and suppresses STAT3 activation, thus to inhibit CXCL 12-induced invasion. Minecoside potently inhibits cancer metastasis and promotes apoptotic progression[1][2].

Product Specifications

CAS Number

[51005-44-8]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

CXCR; STAT

Type

Natural Products

Related Pathways

GPCR/G Protein; Immunology/Inflammation; JAK/STAT Signaling; Stem Cell/Wnt

Applications

COVID-19-immunoregulation

Field of Research

Cancer; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/minecoside.html

Purity

99.86

Smiles

OC[C@@]1([C@]([C@@H]2O[C@@H]([C@@H]([C@H]3O)O)O[C@@H]([C@H]3O)CO)([H])[C@](C=CO2)([H])[C@@H]4OC(/C=C/C(C=C5)=CC(O)=C5OC)=O)[C@@]4([H])O1

Molecular Formula

C25H30O13

Molecular Weight

538.50

Precautions

H302, H315, H319, H335

References & Citations

[1]Kim B, et al. Minecoside Modulates Cell Invasion via Regulation of CXCR4 Expression in Breast and Colon Cancer Cells. Planta Med. 2020 Mar;86 (5) :331-337.|[2]Kim B, et al. Minecoside promotes apoptotic progression through STAT3 inactivation in breast cancer cells. Oncol Lett. 2022 Mar;23 (3) :94.